<DOC>
	<DOCNO>NCT01610284</DOCNO>
	<brief_summary>The purpose study determine wether addition daily BKM120 fulvestrant effective safe treat patient hormone receptor-positive , HER2-negative locally advanced metastatic breast cancer refractory aromatase inhibitor .</brief_summary>
	<brief_title>Phase III Study BKM120/Placebo With Fulvestrant Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced Metastatic Breast Cancer Refractory Aromatase Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Locally advanced metastatic breast cancer HER2negative hormone receptorpositive status ( common breast cancer classification test ) Postmenopausal woman A tumor sample must ship Novartis designated laboratory identification biomarkers ( PI3K activation status ) Progression recurrence breast cancer aromatase inhibitor treatment Measurable disease non measurable disease bone lesion absence measurable disease per RECIST 1.1 Adequate bone marrow organ function define laboratory value Previous treatment PI3K inhibitor , AKT inhibitor , mTOR inhibitor fulvestrant More one prior chemotherapy line metastatic disease Symptomatic brain metastasis Increasing chronic treatment ( &gt; 5 day ) corticosteroids another immunosuppressive agent Active heart ( cardiac ) disease define protocol Certain score anxiety depression mood questionnaires Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Hormone receptor positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>PI3K</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Refractory</keyword>
	<keyword>Aromatase inhibitor</keyword>
</DOC>